Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Tricida, Inc. (TCDA) since 2018 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Tricida, Inc.. (See page 1 of this report.) Table 2 shows the detailed insider transactions. This company's CIK number is 1595585.
Total stock buying since 2018: $103,848,416.
Total stock sales since 2018: $202,439,808.
Total stock option exercises since 2018: $554,369.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2022 | 4,442,691 | $45,021,937 | 21,412,395 | $13,227,475 | 0 | $0 |
| 2021 | 0 | $0 | 274,900 | $1,783,486 | 0 | $0 |
| 2020 | 65,000 | $1,375,018 | 157,750 | $3,859,726 | 51,750 | $89,417 |
| 2019 | 500,000 | $17,862,813 | 4,657,462 | $182,830,316 | 382,316 | $453,552 |
| 2018 | 2,080,792 | $39,588,648 | 29,651 | $738,805 | 14,251 | $11,400 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2019-11-20 | Alpern Robert J | Sale | 2,439 | 40.65 | 99,145 |
| 2019-11-19 | Parker Geoffrey M. (Chief Fin. Officer and Sr. VP) | Buy | 945 | 34.72 | 32,810 |
| 2019-11-18 | Parker Geoffrey M. (Chief Fin. Officer and Sr. VP) | Buy | 19,055 | 34.28 | 653,205 |
| 2019-11-12 | Stahl Wilhelm (Chief Tech Officer & Sr. VP) | Sale | 836 | 39.97 | 33,414 |
| 2019-11-12 | Stahl Wilhelm (Chief Tech Officer & Sr. VP) | Option Ex | 836 | 1.68 | 1,404 |
| 2019-11-12 | Alpern Robert J | Sale | 1,159 | 39.92 | 46,267 |
| 2019-11-07 | Coufal Sandra I | Sale | 100 | 40.02 | 4,002 |
| 2019-11-07 | Stahl Wilhelm (Chief Tech Officer & Sr. VP) | Sale | 2,910 | 39.97 | 116,312 |
| 2019-11-07 | Stahl Wilhelm (Chief Tech Officer & Sr. VP) | Option Ex | 2,910 | 1.68 | 4,888 |
| 2019-11-07 | Alpern Robert J | Sale | 3,953 | 39.93 | 157,843 |
| 2019-11-06 | Stahl Wilhelm (Chief Tech Officer & Sr. VP) | Sale | 48 | 39.97 | 1,918 |
| 2019-11-06 | Stahl Wilhelm (Chief Tech Officer & Sr. VP) | Option Ex | 48 | 1.68 | 80 |
| 2019-11-06 | Alpern Robert J | Sale | 227 | 39.75 | 9,023 |
| 2019-11-05 | Stahl Wilhelm (Chief Tech Officer & Sr. VP) | Sale | 991 | 40.02 | 39,659 |
| 2019-11-05 | Stahl Wilhelm (Chief Tech Officer & Sr. VP) | Option Ex | 991 | 1.68 | 1,664 |
| 2019-11-05 | Alpern Robert J | Sale | 1,605 | 39.89 | 64,023 |
| 2019-11-04 | Stahl Wilhelm (Chief Tech Officer & Sr. VP) | Sale | 2,651 | 39.78 | 105,456 |
| 2019-11-04 | Stahl Wilhelm (Chief Tech Officer & Sr. VP) | Option Ex | 2,651 | 1.68 | 4,453 |
| 2019-11-04 | Alpern Robert J | Sale | 2,617 | 39.84 | 104,261 |
| 2019-11-01 | Coufal Sandra I | Sale | 2,338 | 38.80 | 90,726 |
| 2019-11-01 | Klaerner Gerrit (President and CEO) | Sale | 49,000 | 38.42 | 1,882,530 |
| 2019-11-01 | Lockey Claire (Chief Dev. Officer and Sr. VP) | Sale | 10,548 | 37.90 | 399,800 |
| 2019-11-01 | Lockey Claire (Chief Dev. Officer and Sr. VP) | Option Ex | 10,548 | .76 | 8,016 |
| 2019-11-01 | Veitinger Klaus R Dr | Sale | 5,250 | 38.88 | 204,104 |
| 2019-11-01 | Veitinger Klaus R Dr | Option Ex | 1,750 | .80 | 1,400 |
| 2019-10-28 | Otto Dawn Parsell (Sr VP, Clinical Development) | Sale | 5,300 | 37.48 | 198,628 |
| 2019-10-28 | Otto Dawn Parsell (Sr VP, Clinical Development) | Option Ex | 5,300 | 2.04 | 10,785 |
| 2019-10-28 | Klaerner Gerrit (President and CEO) | Sale | 4,000 | 37.45 | 149,780 |
| 2019-10-25 | Stahl Wilhelm (Chief Tech Officer & Sr. VP) | Sale | 5,000 | 36.33 | 181,650 |
| 2019-10-25 | Stahl Wilhelm (Chief Tech Officer & Sr. VP) | Option Ex | 5,000 | 1.20 | 6,000 |
| 2019-10-25 | Alpern Robert J | Sale | 11,000 | 36.68 | 403,513 |
| 2019-10-25 | Veitinger Klaus R Dr | Sale | 5,250 | 36.30 | 190,574 |
| 2019-10-25 | Veitinger Klaus R Dr | Option Ex | 1,750 | .80 | 1,400 |
| 2019-10-03 | Stahl Wilhelm (Chief Tech Officer & Sr. VP) | Sale | 2,000 | 31.16 | 62,320 |
| 2019-10-03 | Stahl Wilhelm (Chief Tech Officer & Sr. VP) | Option Ex | 2,000 | 1.68 | 3,360 |
| 2019-10-01 | Klaerner Gerrit (President and CEO) | Sale | 11,223 | 31.25 | 350,718 |
| 2019-10-01 | Lockey Claire (Chief Dev. Officer and Sr. VP) | Sale | 10,000 | 31.00 | 309,950 |
| 2019-10-01 | Lockey Claire (Chief Dev. Officer and Sr. VP) | Option Ex | 10,000 | .80 | 8,000 |
| 2019-09-30 | Klaerner Gerrit (President and CEO) | Sale | 10,255 | 30.88 | 316,684 |
| 2019-09-26 | Stahl Wilhelm (Chief Tech Officer & Sr. VP) | Sale | 2,000 | 31.75 | 63,494 |
| 2019-09-26 | Stahl Wilhelm (Chief Tech Officer & Sr. VP) | Option Ex | 2,000 | .72 | 1,440 |
| 2019-09-26 | Alpern Robert J | Sale | 1,000 | 31.85 | 31,847 |
| 2019-09-26 | Veitinger Klaus R Dr | Sale | 4,200 | 31.74 | 133,291 |
| 2019-09-26 | Veitinger Klaus R Dr | Option Ex | 1,400 | .80 | 1,120 |
| 2019-09-25 | Otto Dawn Parsell (Sr VP, Clinical Development) | Sale | 5,300 | 32.65 | 173,029 |
| 2019-09-25 | Otto Dawn Parsell (Sr VP, Clinical Development) | Option Ex | 5,300 | 1.68 | 8,904 |
| 2019-09-04 | Stahl Wilhelm (Chief Tech Officer & Sr. VP) | Sale | 2,000 | 33.37 | 66,730 |
| 2019-09-04 | Stahl Wilhelm (Chief Tech Officer & Sr. VP) | Option Ex | 2,000 | .72 | 1,440 |
| 2019-09-03 | Lockey Claire (Chief Dev. Officer and Sr. VP) | Sale | 10,000 | 34.08 | 340,750 |
| 2019-09-03 | Lockey Claire (Chief Dev. Officer and Sr. VP) | Option Ex | 10,000 | .80 | 8,000 |
| 2019-09-03 | Parker Geoffrey M. (Chief Fin. Officer and Sr. VP) | Option Ex | 54,347 | 1.84 | 99,998 |
| 2019-08-28 | Otto Dawn Parsell (Sr VP, Clinical Development) | Sale | 5,000 | 33.69 | 168,425 |
| 2019-08-28 | Otto Dawn Parsell (Sr VP, Clinical Development) | Option Ex | 5,000 | 1.68 | 8,400 |
| 2019-08-28 | Klaerner Gerrit (President and CEO) | Sale | 4,000 | 33.71 | 134,840 |
| 2019-08-26 | Alpern Robert J | Sale | 1,000 | 33.19 | 33,190 |
| 2019-08-26 | Veitinger Klaus R Dr | Sale | 4,200 | 33.16 | 139,284 |
| 2019-08-26 | Veitinger Klaus R Dr | Option Ex | 1,400 | .80 | 1,120 |
| 2019-08-13 | Parker Geoffrey M. (Chief Fin. Officer and Sr. VP) | Buy | 11,947 | 33.26 | 397,297 |
| 2019-08-12 | Parker Geoffrey M. (Chief Fin. Officer and Sr. VP) | Buy | 18,053 | 32.10 | 579,501 |
| 2019-08-02 | Stahl Wilhelm (Chief Tech Officer & Sr. VP) | Sale | 2,000 | 30.92 | 61,840 |
| 2019-08-02 | Stahl Wilhelm (Chief Tech Officer & Sr. VP) | Option Ex | 2,000 | .72 | 1,440 |
| 2019-08-01 | Lockey Claire (Chief Dev. Officer and Sr. VP) | Sale | 10,000 | 32.02 | 320,200 |
| 2019-08-01 | Lockey Claire (Chief Dev. Officer and Sr. VP) | Option Ex | 10,000 | .80 | 8,000 |
| 2019-07-29 | Otto Dawn Parsell (Sr VP, Clinical Development) | Sale | 5,000 | 31.19 | 155,950 |
| 2019-07-29 | Otto Dawn Parsell (Sr VP, Clinical Development) | Option Ex | 5,000 | 1.68 | 8,400 |
| 2019-07-29 | Klaerner Gerrit (President and CEO) | Sale | 4,000 | 31.17 | 124,680 |
| 2019-07-25 | Alpern Robert J | Sale | 1,000 | 31.60 | 31,600 |
| 2019-07-25 | Veitinger Klaus R Dr | Sale | 4,200 | 31.62 | 132,816 |
| 2019-07-25 | Veitinger Klaus R Dr | Option Ex | 1,400 | .80 | 1,120 |
| 2019-07-08 | Coufal Sandra I | Sale | 380 | 34.63 | 13,159 |
| 2019-07-08 | Klaerner Gerrit (President and CEO) | Sale | 2,596 | 34.63 | 89,912 |
| 2019-07-08 | Stahl Wilhelm (Chief Tech Officer & Sr. VP) | Sale | 3,085 | 34.67 | 106,956 |
| 2019-07-08 | Stahl Wilhelm (Chief Tech Officer & Sr. VP) | Option Ex | 3,085 | .72 | 2,221 |
| 2019-07-05 | Coufal Sandra I | Sale | 1,620 | 36.22 | 58,676 |
| 2019-07-05 | Klaerner Gerrit (President and CEO) | Sale | 3,230 | 36.28 | 117,184 |
| 2019-07-05 | Stahl Wilhelm (Chief Tech Officer & Sr. VP) | Sale | 1,615 | 36.28 | 58,592 |
| 2019-07-05 | Stahl Wilhelm (Chief Tech Officer & Sr. VP) | Option Ex | 1,615 | .72 | 1,162 |
| 2019-07-05 | Veitinger Klaus R Dr | Sale | 3,492 | 36.30 | 126,749 |
| 2019-07-05 | Veitinger Klaus R Dr | Option Ex | 1,100 | .80 | 880 |
| 2019-07-03 | Otto Dawn Parsell (Sr VP, Clinical Development) | Sale | 15,407 | 37.04 | 570,675 |
| 2019-07-03 | Otto Dawn Parsell (Sr VP, Clinical Development) | Option Ex | 15,000 | 1.39 | 20,805 |
| 2019-07-03 | Coufal Sandra I | Sale | 4,000 | 37.03 | 148,120 |
| 2019-07-03 | Klaerner Gerrit (President and CEO) | Sale | 6,874 | 37.08 | 254,853 |
| 2019-07-03 | Stahl Wilhelm (Chief Tech Officer & Sr. VP) | Sale | 3,000 | 36.91 | 110,729 |
| 2019-07-03 | Stahl Wilhelm (Chief Tech Officer & Sr. VP) | Option Ex | 3,000 | .72 | 2,160 |
| 2019-07-03 | Lockey Claire (Chief Dev. Officer and Sr. VP) | Sale | 40,401 | 37.10 | 1,498,877 |
| 2019-07-03 | Lockey Claire (Chief Dev. Officer and Sr. VP) | Option Ex | 40,000 | .80 | 32,000 |
| 2019-07-03 | Alpern Robert J | Sale | 3,000 | 37.05 | 111,149 |
| 2019-07-03 | Veitinger Klaus R Dr | Sale | 9,108 | 36.90 | 336,112 |
| 2019-07-03 | Veitinger Klaus R Dr | Option Ex | 3,100 | .80 | 2,480 |
| 2019-04-03 | Orbimed Capital Gp V Llc | Buy | 225,000 | 36.00 | 8,100,000 |
| 2019-04-03 | Bonita David P | Buy | 225,000 | 36.00 | 8,100,000 |
| 2019-03-28 | Otto Dawn Parsell (Sr VP, Clinical Development) | Sale | 15,500 | 30.74 | 476,470 |
| 2019-03-28 | Otto Dawn Parsell (Sr VP, Clinical Development) | Option Ex | 15,500 | .80 | 12,400 |
| 2019-03-28 | Coufal Sandra I | Sale | 2,000 | 26.70 | 53,400 |
| 2019-03-28 | Klaerner Gerrit (President and CEO) | Sale | 57,822 | 32.92 | 1,903,789 |
| 2019-03-28 | Stahl Wilhelm (Chief Tech Officer & Sr. VP) | Sale | 6,000 | 29.99 | 179,940 |
| 2019-03-28 | Stahl Wilhelm (Chief Tech Officer & Sr. VP) | Option Ex | 6,000 | .72 | 4,320 |
| 2019-03-28 | Lockey Claire (Chief Dev. Officer and Sr. VP) | Sale | 52,925 | 35.00 | 1,852,375 |
| 2019-03-28 | Lockey Claire (Chief Dev. Officer and Sr. VP) | Option Ex | 52,925 | 1.64 | 86,691 |
| 2019-03-28 | Alpern Robert J | Sale | 14,000 | 33.63 | 470,820 |
| 2019-03-28 | Veitinger Klaus R Dr | Sale | 66,300 | 34.19 | 2,266,598 |
| 2019-03-28 | Veitinger Klaus R Dr | Option Ex | 22,100 | .80 | 17,680 |
| 2019-03-26 | Veitinger Klaus R Dr | Sale | 12,000 | 23.83 | 285,960 |
| 2019-03-26 | Veitinger Klaus R Dr | Option Ex | 4,000 | .80 | 3,200 |
| 2019-03-18 | Otto Dawn Parsell (Sr VP, Clinical Development) | Sale | 1,729 | 25.02 | 43,259 |
| 2019-03-18 | Otto Dawn Parsell (Sr VP, Clinical Development) | Option Ex | 1,729 | .80 | 1,383 |
| 2019-03-18 | Lockey Claire (Chief Dev. Officer and Sr. VP) | Sale | 14,681 | 25.23 | 370,401 |
| 2019-03-18 | Lockey Claire (Chief Dev. Officer and Sr. VP) | Option Ex | 14,681 | .80 | 11,744 |
| 2019-03-15 | Otto Dawn Parsell (Sr VP, Clinical Development) | Sale | 771 | 25.02 | 19,290 |
| 2019-03-15 | Otto Dawn Parsell (Sr VP, Clinical Development) | Option Ex | 771 | .80 | 616 |
| 2019-03-15 | Lockey Claire (Chief Dev. Officer and Sr. VP) | Sale | 1,825 | 25.02 | 45,661 |
| 2019-03-15 | Lockey Claire (Chief Dev. Officer and Sr. VP) | Option Ex | 1,825 | .80 | 1,460 |
| 2019-03-14 | Lockey Claire (Chief Dev. Officer and Sr. VP) | Sale | 1,508 | 25.02 | 37,730 |
| 2019-03-14 | Lockey Claire (Chief Dev. Officer and Sr. VP) | Option Ex | 1,508 | .80 | 1,206 |
| 2019-03-13 | Otto Dawn Parsell (Sr VP, Clinical Development) | Sale | 2,000 | 25.00 | 50,000 |
| 2019-03-13 | Otto Dawn Parsell (Sr VP, Clinical Development) | Option Ex | 2,000 | .80 | 1,600 |
| 2019-03-13 | Lockey Claire (Chief Dev. Officer and Sr. VP) | Sale | 11,986 | 25.01 | 299,769 |
| 2019-03-13 | Lockey Claire (Chief Dev. Officer and Sr. VP) | Option Ex | 11,986 | .80 | 9,588 |
| 2019-03-04 | Klaerner Gerrit (President and CEO) | Sale | 853 | 23.76 | 20,267 |
| 2019-03-01 | Klaerner Gerrit (President and CEO) | Sale | 7,147 | 23.93 | 171,063 |
| 2019-02-28 | Coufal Sandra I | Sale | 2,000 | 23.04 | 46,080 |
| 2019-02-25 | Veitinger Klaus R Dr | Sale | 12,000 | 22.60 | 271,164 |
| 2019-02-25 | Veitinger Klaus R Dr | Option Ex | 4,000 | .80 | 3,200 |
| 2019-01-30 | Coufal Sandra I | Sale | 28 | 20.10 | 562 |
| 2019-01-29 | Coufal Sandra I | Sale | 972 | 20.09 | 19,527 |
| 2019-01-28 | Coufal Sandra I | Sale | 1,000 | 20.35 | 20,350 |
| 2019-01-28 | Veitinger Klaus R Dr | Sale | 6,000 | 20.31 | 121,878 |
| 2019-01-28 | Veitinger Klaus R Dr | Option Ex | 2,000 | .80 | 1,600 |
| 2019-01-25 | Veitinger Klaus R Dr | Sale | 6,000 | 20.86 | 125,178 |
| 2019-01-25 | Veitinger Klaus R Dr | Option Ex | 2,000 | .80 | 1,600 |
| 2019-01-07 | Otto Dawn Parsell (Sr VP, Clinical Development) | Sale | 665 | 23.27 | 15,474 |
| 2019-01-02 | Lockey Claire (Chief Dev. Officer and Sr. VP) | Sale | 684 | 23.59 | 16,135 |
| 2018-12-27 | Veitinger Klaus R Dr | Sale | 2,437 | 23.72 | 57,798 |
| 2018-12-27 | Veitinger Klaus R Dr | Option Ex | 997 | .80 | 797 |
| 2018-12-26 | Coufal Sandra I | Sale | 3,400 | 25.08 | 85,272 |
| 2018-12-26 | Klaerner Gerrit (President and CEO) | Sale | 4,000 | 25.02 | 100,080 |
| 2018-12-26 | Lockey Claire (Chief Dev. Officer and Sr. VP) | Sale | 10,000 | 25.06 | 250,600 |
| 2018-12-26 | Lockey Claire (Chief Dev. Officer and Sr. VP) | Option Ex | 10,000 | .80 | 8,000 |
| 2018-12-26 | Veitinger Klaus R Dr | Sale | 9,814 | 24.97 | 245,055 |
| 2018-12-26 | Veitinger Klaus R Dr | Option Ex | 3,254 | .80 | 2,603 |
| 2018-11-13 | Parker Geoffrey M. (Chief Fin. Officer and Sr. VP) | Buy | 5,000 | 29.72 | 148,600 |
| 2018-07-02 | Sibling Co-investment Llc (Other) | Buy | 463,158 | 19.00 | 8,800,002 |
| 2018-07-02 | Coufal Sandra I | Buy | 463,158 | 19.00 | 8,800,002 |
| 2018-07-02 | Klaerner Gerrit (President and CEO) | Buy | 15,790 | 19.00 | 300,010 |
| 2018-07-02 | Hejlek Edward J (SVP, General Counsel & Secy.) | Buy | 13,158 | 19.00 | 250,002 |
| 2018-07-02 | Van Beek Jeroen B (Chief Comm Officer and Sr VP) | Buy | 5,264 | 19.00 | 100,016 |
| 2018-07-02 | Pietzke Steffen (VP Fin & Chief Acct Officer) | Buy | 10,527 | 19.00 | 200,013 |
| 2018-07-02 | Hirsch David | Buy | 131,579 | 19.00 | 2,500,001 |
| 2018-07-02 | Orbimed Capital Gp V Llc | Buy | 368,421 | 19.00 | 6,999,999 |
| 2018-07-02 | Stahl Wilhelm (Chief Tech Officer & Sr. VP) | Buy | 13,158 | 19.00 | 250,002 |
| 2018-07-02 | Bonita David P | Buy | 368,421 | 19.00 | 6,999,999 |
| 2018-07-02 | Parker Geoffrey M. (Chief Fin. Officer and Sr. VP) | Buy | 60,000 | 19.00 | 1,140,000 |
| 2018-07-02 | Enright Patrick G | Buy | 131,579 | 19.00 | 2,500,001 |
| 2018-07-02 | Falberg Kathryn E | Buy | 31,579 | 19.00 | 600,001 |
Insider trading activities including stock purchases, stock sales, and option exercises of TCDA listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Tricida, Inc. (symbol TCDA, CIK number 1595585) see the Securities and Exchange Commission (SEC) website.